HBM HOLDINGS-B (02142) partner Spruce spins off the CRHX-101 project into Adrenyx; Adrenyx plans to list on Nasdaq in the first half of 2027
HBM HOLDINGS-B (02142) announced that its partner Spruce Biosciences Inc. (Nasdaq stock code: SPRB) (Spruce) has spun off its CRHX-101 (also known as HBM9013/HAT001/SPR-202) project into Adrenyx Biosciences, Inc. (Adrenyx), a newly established wholly-owned subsidiary of Spruce, and Adrenyx is expected to list on Nasdaq in the first half of 2027.
HBM HOLDINGS-B (02142) announces that its partner Spruce Biosciences Inc. (Nasdaq stock code: SPRB) (Spruce) has spun off its CRHX-101 (also known as HBM9013/HAT001/SPR-202) project into Adrenyx Biosciences, Inc. (Adrenyx), a newly established wholly-owned subsidiary of Spruce, and Adrenyx is expected to list on Nasdaq in the first half of 2027. Upon completion of the planned pro rata distribution of Adrenyx common shares to Spruce shareholders, HBM Holdings expects to hold equity interests in both Spruce and Adrenyx simultaneously. CRHX-101 is a monoclonal antibody designed and developed for the treatment of congenital adrenal hyperplasia. Adrenyx intends to submit an Investigational New Drug application for CRHX-101 to the U.S. Food and Drug Administration and thereafter initiate clinical development.
CRHX-101 originated from HBM Alpha Therapeutics (HBMAT), a subsidiary in which the Company holds a majority interest. In January 2025, HBMAT entered into a collaboration and license agreement with Spruce, granting Spruce exclusive global rights to develop and commercialize CRHX-101 outside Greater China (mainland China, Taiwan, Hong Kong and Macau).
Related Articles

HK Stock Market Move | XPENG-W (09868) Rises Over 3% Again; Strong Q4 Guidance; Company's Physical AI Commercialization Milestones Landing Densely

BOCI: Raises HWORLD-S (01179) target price to HK$49.3, maintains "Buy" rating

Guotai Haitong: Geopolitical expectations cause short-term disruption in oil shipping; value highlights contrarian positioning
HK Stock Market Move | XPENG-W (09868) Rises Over 3% Again; Strong Q4 Guidance; Company's Physical AI Commercialization Milestones Landing Densely

BOCI: Raises HWORLD-S (01179) target price to HK$49.3, maintains "Buy" rating

Guotai Haitong: Geopolitical expectations cause short-term disruption in oil shipping; value highlights contrarian positioning






